FDA Emergency Use Authorization Approval for ZEUS ELISA SARS-CoV-2 Total Antibody Test System


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Now ELISA bases Covid test from Zeus Scientific

ZEUS Scientific has been granted by the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its in vitro ELISA diagnostic test for the qualitative detection of total antibodies to the SARS-CoV-2 virus in human serum and plasma. ZEUS has been producing and shipping the ELISA SARS-CoV-2 Total Antibody Test System since June 2020 and has steadily increased production capabilities to keep up with the growing demand. Achieving EUA approval was the next step in ZEUS’s commitment to deliver superior quality COVID-19 antibody detection devices. The ZEUS ELISA SARS-CoV-2 Total Antibody Test System joins our previously EUA-approved ZEUS ELISA SARS-CoV-2 IgG Test System.

The ZEUS ELISA SARS-CoV-2 Total Antibody Test System is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The assay utilizes a dual antigen combination of recombinant S1 receptor binding domain (RBD) viral protein and recombinant nucleoprotein for optimal performance. By detecting a total antibody response to both the Nucleocapsid and Spike SARS-CoV-2 antigens the test is uniquely positioned as an ideal serological screening assay or first tier assay in an orthogonal testing algorithm as it can detect what others may miss.

Using FDA authorized RT-PCR assays as the reference method, the ELISA test demonstrated 96.0% positive agreement. A 98.9% negative agreement was demonstrated using a cohort comprised of RT-PCR negative specimens. Specificity of 100% was achieved using a cohort of pre-pandemic healthy donors. More details on the test system performance can be found on our website.

The SARS-CoV-2 Total Antibody Test System assay follows ZEUS’s universal ELISA assay protocol. This protocol offers a high degree of flexibility with incubation times (20-30 minutes for sample incubation and conjugate incubation, 10-15 minutes for TMB substrate incubation) allowing for simple, efficient, and flexible automation programming on open pipetting systems. ZEUS has received FDA authorization to run the ZEUS ELISA SARS-SoV-2 Total Antibody Test System manually or using the Dynex Agility, Dynex DSX or Dynex DS2 Automated ELISA Systems. The Agility offers a high throughput and takes advantage of the SmartKit Gold packaging, providing the ability to fully automate the procedure from sample to result in a throughput meeting all laboratory requirements. The new Test System also includes our proprietary SAVe Diluent, a unique component which changes color when serum is added ensuring no well is missed!

For over 40 years, laboratories have trusted ZEUS Scientific to provide high quality in vitro diagnostic immunoassays for numerous infectious diseases. With over 125 FDA cleared assays in our menu, our company has a proven skillset of developing, manufacturing distributing and delivering a family of products to aid in the diagnosis of complex infectious agents including a variety of known viral pathogens. We welcome you to explore our ELISA menu to see how ZEUS is capable of helping your lab today accommodate increased immunoassay testing demand.

We have concentrated our focus to the COVID-19 pandemic and the SARS-CoV-2 virus. Both ZEUS SARS-CoV-2 ELISA products are in stock and ready to ship today.

Tags : #ZeusScientific #FDA #ELISATestSARSCOV #Antibody #SAARS #FDANews #Immunoassays

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026